ScicCone Pharmaceuticals Inc. (SCLN1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Friedhelm Blobel
Employees:
570
950 TOWER LANE, SUITE 900, FOSTER CITY, CA 94404-2125
650-358-3456

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

SciClone Pharmaceuticals, Inc. engages in the development of therapeutics treatment for cancer, infectious diseases, and cardiovascular disorders. Its product portforlio includes ZADAXIN, Holxan, Mesna, Endoxan, Farlutal, Methotrexate. Estracyt, Neucardin, Loramyc, and DC Bead. The company was founded in 1990 and is headquartered in Foster City, CA.

Data derived from most recent annual or quarterly report
Market Cap 581.939 Million Shares Outstanding52.192 Million Avg 30-day Volume 493.217 Thousand
P/E Ratio13.5235 Dividend Yield0.0 EPS0.52
Price to Revenue3.4053 Debt to Equity0.0 EBITDA46.617 Million
Price to Book Value2.3443 Operating Margin25.8182 Enterprise Value427.72 Million
Current Ratio8.362 EPS Growth0.108 Quick Ratio7.432
1 Yr BETA 0.7228 52-week High/Low 0.0 / Profit Margin25.1805
Operating Cash Flow Growth2.7129 Altman Z-Score14.4008 Free Cash Flow to Firm 24.739 Million
View SEC Filings from SCLN1 instead.

View recent insider trading info

ScicCone Pharmaceuticals Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding SCLN1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SCLN1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SAXE JON S

  • Director
 No longer subject to file 2017-10-13 0

CHANG NANCY T

  • Director
 No longer subject to file 2017-10-13 0

CHEUNG WILSON WAI-SHUN CFO & SENIOR VP, FINANCE

  • Officer
 No longer subject to file 2017-10-13 0

HAWKINS RICHARD J

  • Director
 No longer subject to file 2017-10-13 0

LAPOINTE ANTHONY GREGG

  • Director
 No longer subject to file 2017-10-13 0

BLOBEL FRIEDHELM PRESIDENT, CEO, DIRECTOR

  • Officer
  • Director
 No longer subject to file 2017-10-13 0

LOW RAYMOND ANTHONY VP, FINANCE & CONTROLLER

  • Officer
  • Director
 No longer subject to file 2017-10-13 0

XIE LAN VP FINANCE, CHINA CFO

  • Officer
 No longer subject to file 2017-10-13 0

LI SIMON

  • Director
 No longer subject to file 2017-10-13 0

ZHAO HONG CEO, CHINA OPERATIONS

  • Officer
 No longer subject to file 2017-10-13 0

CHERN CAREY GENERAL COUNSEL

  • Officer
 No longer subject to file 2017-10-13 0

ALLY BRIDGE LB HEALTHCARE MASTER FUND LTD

ALLY BRIDGE LB MANAGEMENT LTD

ABG MANAGEMENT LTD

YU FAN

LI BIN

  • FORMER MEMBER, 10% OWNER GROUPSEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKS
 No longer subject to file 2017-02-17 0

MENG CHUNCAI GEN. COUNSEL & VP COMPLIANCE

  • Officer
 0 2016-08-12 0

KING ROBERT SVP OF PROD. DEV/SUPPLY CHAIN

  • Officer
 16,844 2016-08-12 0

GL PARTNERS CAPITAL MANAGEMENT LTD

GL CAPITAL MANAGEMENT GP LTD

  • 10% Owner
 4,750,116 2016-02-22 0

DRAGON ALPHA LP

JADE PARK INVESTMENTS LTD

LIU LANCHU

  • SEE REMARKSSEE REMARKSSEE REMARKS
 26,664 2016-02-22 0

YIN MIN VP COMPLIANCE & INTERNAL AUDIT

  • Officer
 0 2014-03-14 0

TSO WINNIE WING-KEI

  • VP, FINANCE AND CONTROLLER
 0 2013-08-01 0

WONG STEPHANIE VP, FINANCE AND CONTROLLER

  • Officer
 0 2013-04-04 0

BARRETT PETER

  • Director
 0 2012-06-07 0

LAWRENCE IRA D

  • Director
 0 2012-06-07 0

GUAN JIE JACKIE CHIEF OPERATING OFFICER

  • Officer
 0 2012-06-07 0

TITUS GARY SENIOR VP FINANCE & CFO

  • Officer
 277,554 2012-05-31 0

SIGMA TAU FINANZIARIA SPA

DEFIANTE FARMACEUTICA LDA

  • 10% Owner
 No longer subject to file 2012-04-30 0

CAVAZZA PAOLO

  • 10% Owner
 No longer subject to file 2012-04-30 0

RIOS ISRAEL SR. VP, MEDICAL AFFAIRS & CMO

  • Officer
 0 2012-03-15 0

LOTTER MARK CEO, CHINA OPERATIONS

  • Officer
 0 2012-03-15 0

JONES TREVOR M

  • Director
 0 2011-06-30 0

CAMERINI ROBERTO

  • Director
 0 2011-06-14 0

WOODMAN DEAN S

  • Director
 70,000 2011-05-23 0

CHAUMIERE CONSULTADORIA & SERVICOS SDC UNIPESSOAL LDA

  • MEMBER OF 10% OWNER GROUP
 No longer subject to file 2010-06-29 0

SINAF S.A.

  • MEMBER OF 10% OWNER GROUP
 1,289,052 2010-06-29 0

SCHMID HANS P PRES & MNG DIR, SCICLONE INT'L

  • Officer
 0 2010-05-14 0

HUI IVAN PRINCIPAL ACCOUNTING OFFICER

  • Officer
 No longer subject to file 2009-05-22 0

BAXTER JOHN D

  • Director
 371,492 2009-05-21 0

HENEL ROLF H

  • Director
 60,000 2009-05-14 0

APTAFIN S P A

  • MEMBER OF 10% OWNER GROUP
 765,841 2008-12-11 0

CAVAZZA CLAUDIO

  • 10% Owner
 6,975,553 2008-01-30 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments